Jisandai (Epclusa) latest price and market purchase reference in 2025

Epclusa (Epclusa/Epclusa) is an oral antiviral drug for the treatment of hepatitis C. It has been officially launched in China and has been included in the medical insurance catalog. This means that eligible patients can purchase and enjoy the medical insurance reimbursement policy at domestic hospital pharmacies, thereby reducing treatment costs to a certain extent and improving drug accessibility.

According to2025 market information, the domestic price of Jisandai is about more than 3,000 yuan per box. The specific costs vary depending on the region, hospital and medical insurance reimbursement ratio. Therefore, patients should consult the local hospital pharmacy before purchasing to confirm the latest price and medical insurance reimbursement policy to reasonably arrange the treatment budget.

In foreign markets, the price of Jisanda's Indian and Bangladeshi generic drugs is relatively low, only a few hundred yuan per box, and the drug ingredients are basically the same as the domestic original drugs. This provides options for some patients who want to reduce treatment costs, but they need to pay attention to the legality, quality and transportation channels of the drugs to avoid purchasing unverified drugs.

When patients choose to purchase Jisanda, they should give priority to obtaining original drugs or drugs covered by medical insurance through regular domestic hospital pharmacies to ensure safety and efficacy. If you consider overseas generic drugs, you should use them under the guidance of a professional doctor, and pay attention to drug packaging, sources and legal import channels. During the period of medication, patients should strictly follow the dosage and treatment requirements, and regularly review liver function and virological indicators to achieve optimal efficacy and safe medication.

Reference materials:https://www.drugs.com/